Organization
UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA
13 abstracts
Abstract
Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?Org: Department of Medicine (DMED), University of Udine, Aviano, Italy, Washington University in St. Louis, St. Louis, MO, Universita degli Studi di Udine, Udine, Italy, Weill Cornell Medicine, New York, NY, Massachusetts General Hospital Cancer Center, Boston, MA,
Abstract
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Dana-Farber Cancer Institute, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study.Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Massachusetts General Hospital, Harvard Medical School, Washington University in St. Louis, Natera, Inc.,
Abstract
Nectin-4 expression in primary breast cancer and associated clinical outcomes.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Broad Institute of Harvard and MIT, Massachusetts General Hospital, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
Accelerated epigenetic aging and risk of chemotoxicity in older adults with early breast cancer.Org: City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
A phase II randomized double-blind placebo-controlled study of fisetin to improve physical function in frail older breast cancer survivors (TROFFi).Org: City of Hope National Medical Center, City of Hope National Comprehensive Cancer Center, University of California, Los Angeles, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Assessing mail-in cryopreservation for fertility preservation.Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Shady Grove Fertility Reproductive Science Center, Departments of Urology and Epidemiology & Biostatistics, Fellow Health, San Leandro, CA, Yale Medicine,
Abstract
Clinical analysis of optimized neural network risk models to predict clinically significant prostate cancer and avoid unnecessary prostate biopsies.Org: Nanostics Inc., University of Alberta, University of Calgary, Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Johns Hopkins Kimmel Cancer Center,
Abstract
Association of lymph node examination during resection with overall survival (OS) and healthcare costs in patients with early non–small-cell lung cancer (eNSCLC).Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Genentech Inc., Genesis Research,
Abstract
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETYOrg: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, Octapharma PPG, Phoenix Neurological Associates, Hospitals in different countries worldwide,